Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun 12:10:1326.
doi: 10.3389/fimmu.2019.01326. eCollection 2019.

Membranous Nephropathy (MN) Recurrence After Renal Transplantation

Patrizia Passerini  1 , Silvia Malvica  1 , Federica Tripodi  1 , Roberta Cerutti  1 , Piergiorgio Messa  1   2
Affiliations
Review

Membranous Nephropathy (MN) Recurrence After Renal Transplantation

Patrizia Passerini et al. Front Immunol. .

Abstract

Primary membranous nephropathy (MN) is a frequent cause of NS in adults. In native kidneys the disease may progress to ESRD in the long term, in some 40-50% of untreated patients. The identification of the pathogenic role of anti-podocyte autoantibodies and the development of new therapeutic options has achieved an amelioration in the prognosis of this disease. MN may also develop in renal allograft as a recurrent or a de novo disease. Since the de novo MN may have some different pathogenetic and morphologic features compared to recurrent MN, in the present paper we will deal only with the recurrent disease. The true incidence of the recurrent form is difficult to assess. This is mainly due to the variable graft biopsy policies in kidney transplantation, among the different transplant centers. Anti-phospholipase A2 receptor (PLA2R) autoantibodies are detected in 70-80% of patients. The knowledge of anti-PLA2R status before transplant is useful in predicting the risk of recurrence. In addition, the serial survey of the anti-PLA2R titers is important to assess the rate of disease progression and the response to treatment. Currently, there are no established guidelines for prevention and treatment of recurrent MN. Symptomatic therapy may help to reduce the signs and symptoms related to the nephrotic syndrome. Anecdotal cases of response to cyclical therapy with steroids and cyclophosphamide have been published. Promising results have been reported with rituximab in both prophylaxis and treatment of recurrence. However, these results are based on observational data, and prospective controlled trials are still missing.

Keywords: anti-PLA2R antibodies; kidney transplant; membranous nephropathy; prognosis; proteinuria; recurrent membranous nephropathy; rituximab.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Antibody-guided diagnosis and treatment algorithm for recurrent MN. RAS-I Renin- angiotensin system inhibitors, PLA2R anti-phospholipase A2 receptor, THSD7A anti- thrombospondin 1 type 1 domain containing 7A. Question marks on optional points.
See this image and copyright information in PMC

References

    1. Ronco P, Debiec H. Molecular pathomechanisms of membranous nephropathy: from Heymann nephritis to alloimmunization. J Am Soc Nephrol. (2005) 16:1205–13. 10.1681/ASN.2004121080 - DOI - PubMed
    1. Nawaz FA, Larsen CP, Troxell ML. Membranous nephropathy and nonsteroidal anti-inflammatory agents. Am J Kidney Dis. (2013) 62:1012–7. 10.1053/j.ajkd.2013.03.045 - DOI - PubMed
    1. Glassock RJ. Diagnosis and natural course of membranous nephropathy. Semin Nephrol. (2003) 23:324–32. 10.1016/S0270-9295(03)00049-4 - DOI - PubMed
    1. Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillon JJ. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. (2008) 73:117–25. 10.1038/sj.ki.5002628 - DOI - PubMed
    1. Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care. Lancet. (2015) 385:1983–92. 10.1016/S0140-6736(15)60731-0 - DOI - PubMed

MeSH terms

Substances